Clemens M R, Göser R, Keller E, Zubke W, Traut H, Schindler A E
Arch Gynakol. 1978 May 12;225(2):91-101. doi: 10.1007/BF00670845.
18 pregnancies occurred after treatment with bromoergocryptine in 17 patients who wished to conceive, but who suffered from anovulation of varying aetiology. The course of 15 pregnancies was uneventful. Three pregnancies ended in abortion. Nine of the 17 women had hyperprolactinemic amenorrhea. Furthermore, one woman had normoprolactinemic post-pill amenorrhea, another normoprolactinemic anovulatory oligomenorrhea and a third normoprolactinemic anovulatory regular menstruations. With the exception of one woman, all had galactorrhea. The courses of pregnancy were monitored by frequent ultrasound measurements of the fetal biparietal diameter, maternal urinary estriol excretion and radioimmunological measurements of plasma estrone, estradiol, unconjugated and immunoreactive estriol, progesterone, and HPL. All data were within the normal ranges and all babies were healthy at birth and had no teratogenic defects. The data prove the great value of bromoergocryptine in the treatment of hyperprolactinemic anovulation, sometimes even in the treatment of normoprolactinemic anovulation. Moreover, the results indicate no adverse effect on either the course or the outcome of pregnancy.
17名患有不同病因无排卵症且希望怀孕的患者在接受溴隐亭治疗后成功怀孕18次。其中15次妊娠过程顺利，3次妊娠以流产告终。17名女性中有9名患有高催乳素血症闭经。此外，1名女性患有正常催乳素水平的 pill 后闭经，另1名患有正常催乳素水平的无排卵性稀发月经，第3名患有正常催乳素水平的无排卵性规律月经。除1名女性外，其他均有溢乳现象。通过频繁超声测量胎儿双顶径、母体尿雌三醇排泄量以及放射免疫法测量血浆雌酮、雌二醇、非结合和免疫反应性雌三醇、孕酮和人胎盘催乳素对妊娠过程进行监测。所有数据均在正常范围内，所有婴儿出生时均健康，无致畸缺陷。这些数据证明了溴隐亭在治疗高催乳素血症无排卵症方面的巨大价值，有时甚至在治疗正常催乳素水平无排卵症方面也有价值。此外，结果表明对妊娠过程或结局均无不良影响。
